Transplant or CAR T-cell Therapy for Lymphoma? How to Make the Choice

Learn the pros and cons of a stem cell transplant, compared to CAR T-cell therapy, for patients with lymphoma.

Printer-friendly version Tuesday, October 24, 2023

 

Transplant or CAR T-cell Therapy for Lymphoma?
How to Make the Choice

Tuesday, October 24th, 2023
1 pm Eastern, Noon Central, 11 am Mountain, 10 am Pacific

In this webinar you will learn:

  • The criteria used to determine whether a stem cell transplant or CAR T-cell therapy is the best treatment option for a patient with lymphoma

  • Steps involved in preparing for, undergoing and recovering from a stem cell transplant compared to CAR T-cell therapy

  • Potential short and long-term side effects of a stem cell transplant compared to CAR T-cell therapy 

  • Likelihood of a cure and quality of life following a stem cell transplant compared to CAR T-cell therapy

  • Treatment options if a patient does not achieve or remain in remission following a stem cell transplant or CAR T-cell therapy

Bring your questions!

The webinar is free, but advance registration is required.  All you will need to participate is a computer, smartphone, or another electronic device.

About the Speaker 

Daniel J. Landsburg, MD is an Associate Professor of Clinical Medicine in the Division of Hematology/Oncology at the Perelman School of Medicine of the University of Pennsylvania.  His clinical practice is focused in lymphoma with a particular interest in treatment of patients with aggressive B cell lymphomas, and his main research interest involves the use of molecular testing to predict outcomes and guide treatment decisions for patients diagnosed with aggressive B cell lymphomas.  He is the Medical Director of Infusion Services and the Physician Leader of the Oncology Clinical Effectiveness Team at the Hospital of the University of Pennsylvania (HUP), and is also a leader in healthcare quality education for hematology/oncology fellows and internal medicine residents training at HUP.

Many thanks to Kite, a Gilead Company for support of this webinar